Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Myoinositol on Serum Asprosin in PCOS
NCT05951309Completed
- Start
- Sep 2021
- Primary completion
- Sep 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of myo-inositol, bCalm and folic acid in polycystic ovary syndrome (PCOS) and insulin resistance (IR) (2 arms). Primary endpoint: Serum asprosin levels. Started Sep 2021; status: completed.
02
Drugs
myo-inositolbCalmfolic acid
03
Conditions
polycystic ovary syndrome (PCOS)insulin resistance (IR)
Beyond the preview
Go deeper on NCT05951309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05951309.